| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/06/2004 | US6759049 Pharmaceutical or dietetic mushroom-based compositions |
| 07/06/2004 | US6759042 Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent |
| 07/06/2004 | CA2303594C Compounds for treating and preventing diabetic complications |
| 07/06/2004 | CA2278759C Process for preparing synthetic soil-extract materials and medicaments based thereon |
| 07/01/2004 | WO2004055185A1 Novel protein and dna thereof |
| 07/01/2004 | WO2004055184A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE |
| 07/01/2004 | WO2004055009A1 Novel compounds having selective inhibiting efect at gsk3 |
| 07/01/2004 | WO2004055006A1 Novel compounds having selective inhibiting effect at gsk3 |
| 07/01/2004 | WO2004055005A1 Novel compounds having selective inhibiting effect at gsk3 |
| 07/01/2004 | WO2004054981A1 5-aminophenanthridine derivatives as npy-5 antagonists |
| 07/01/2004 | WO2004054967A1 Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity |
| 07/01/2004 | WO2004054620A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent |
| 07/01/2004 | WO2004054618A1 Drugs for inhibiting rejection reaction in tissue transplanted into mammalian tissue and method of treating diabetes using the same |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054609A1 Placental alkaline phosphatase to control diabetes |
| 07/01/2004 | WO2004054601A2 Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis |
| 07/01/2004 | WO2004054594A1 Cell death inhibitor |
| 07/01/2004 | WO2004054573A1 Method and composition for inhibiting carbohydrate digestion |
| 07/01/2004 | WO2004054567A1 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause |
| 07/01/2004 | WO2004054356A2 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 07/01/2004 | WO2004017906A3 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 07/01/2004 | WO2004016612A3 New purine derivatives |
| 07/01/2004 | WO2004014298A3 Composition and method for lowering cholesterol |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003003986A3 Parathyroid hormone antibodies and related methods |
| 07/01/2004 | WO2002100341A3 Compounds for the treatment of metabolic disorders |
| 07/01/2004 | WO2002015846A3 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 07/01/2004 | US20040128707 Animal model for pancreatic disorder associated with signal transduction; obesity prevention |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127712 Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127555 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis |
| 07/01/2004 | US20040127550 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 07/01/2004 | US20040127546 for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 07/01/2004 | US20040127482 Substituted heterocycle fused gamma-carbolines |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127466 treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form |
| 07/01/2004 | US20040127462 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae |
| 07/01/2004 | US20040127460 Use of pullulan as a slowly digested carbohydrate |
| 07/01/2004 | US20040127452 C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127399 complex consisting of a divalent metal cation associated with and capable of co-precipitating with such a peptide for enhancing the expression of insulin from mammalian pancreatic B-type islet cells |
| 07/01/2004 | US20040126841 Novel G-protein coupled receptor, HLTEX11 |
| 07/01/2004 | US20040126801 Novel polynucleotides and encoded polypeptides |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126444 Cactaceae-based formulation having the property of fixing fats and method for obtaining same |
| 07/01/2004 | US20040126424 comprises stiffening agents for ameliorating side effects associated with adminstration of lipase inhibitors (anal leakage of undigested fat or oil); for treatment of diabetes |
| 07/01/2004 | US20040126410 Method for preparing zinc-oligopeptide easily absorbable by the human body |
| 07/01/2004 | US20040126367 Oxidation resistance; storage at low temperature; overcoated with liposomes from soybean lecithin |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126356 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 07/01/2004 | CA2509356A1 Glucose and/or fructose transporter naglt1 and its gene |
| 07/01/2004 | CA2509104A1 5-aminophenanthridine derivatives as npy-5 antagonists |
| 07/01/2004 | CA2508045A1 Novel compounds having selective inhibiting efect at gsk3 |
| 07/01/2004 | CA2506685A1 Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity |
| 06/30/2004 | EP1433786A1 Benzoxazole compound and pharmaceutical composition containing the compound |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433776A1 Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| 06/30/2004 | EP1432803A2 Fragments of the human zn-alpha2-glycoprotein and their use in methods of treatment of obesity |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432730A2 Glucagon-like peptide-1 analogs |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432693A2 Mch receptor antagonists |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432682A1 Process for the preparation of repaglinide |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432433A2 Antagonists |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432430A2 Pre-mixes of glp-1 and basal insulin |
| 06/30/2004 | EP1432425A1 A method of reducing the "in vivo" cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 06/30/2004 | EP1432423A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 06/30/2004 | EP1432421A1 Quinoline derivatives as neuropeptide y antagonists |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432310A2 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| 06/30/2004 | EP1385509A4 Method of treatment |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1237857B1 New phenalkyloxy-phenyl derivatives |
| 06/30/2004 | EP1214313B1 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/30/2004 | EP1019408B1 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES |
| 06/30/2004 | EP1009743B1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation |
| 06/30/2004 | EP0851876B1 Antisecretory factor peptides regulating pathological permeability changes |
| 06/30/2004 | EP0765385B1 COMPOSITIONS AND METHOD OF STIMULATING THE PROLIFERATION AND DIFFERENTIATION OF HUMAN FETAL AND ADULT PANCREATIC CELLS $i(EX VIVO) |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509328A Use of opg ligand to modulate immune response |
| 06/30/2004 | CN1509294A High density lipoprotein-reactive peptides |
| 06/30/2004 | CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |